Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TRIUMPH: Tilarginine Acetate in Cardiogenic Shock
NCT00112281Phase 3Terminated
- Sponsor
- Arginox Pharmaceuticals
- Start
- May 2005
- Modality
- Orthosteric Ligands
- Countries
- 2
01
Overview
A Phase 3 trial of NG-monomethyl-L-arginine in cardiogenic shock, sponsored by Arginox Pharmaceuticals. Started May 2005; status: terminated.
02
Drugs
NG-monomethyl-L-arginine
03
Conditions
cardiogenic shock
Beyond the preview
Go deeper on NCT00112281.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00112281.